Evidence map›Paper›PMID 41676355›Full record

ArticleResearch and practice in thrombosis and haemostasis2026

Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI/FXIa dual-domain antibody, following single ascending doses in healthy Chinese subjects.

Jie Huang, Jinlong Liu, Yaxin Liu, Yichen Cao, Wei Sun, Yanrong Dong, Yuwei Li, Jing Li, Qian Wu, Xiaoyan Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jie HuangDepartment of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Jinlong LiuDepartment of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Yaxin LiuCenter of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.
Yichen CaoCenter of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.
Wei SunSuzhou Alphamab Co, Ltd, Suzhou, China.
Yanrong DongSuzhou Alphamab Co, Ltd, Suzhou, China.
Yuwei LiSuzhou Alphamab Co, Ltd, Suzhou, China.
Jing LiSuzhou Alphamab Co, Ltd, Suzhou, China.
Qian WuResearch Center of Drug Clinical Evaluation of Central South University, Changsha, China.
Xiaoyan YangCenter of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.
Shuang YangCenter of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, China.
Chuanpin ChenDepartment of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Guoping YangDepartment of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: KN060 is a humanized dual-domain antibody targeting coagulation factor XI (FXI) and factor XIa (FXIa) and is currently being developed for the prevention of thromboembolic diseases. Objectives: This study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous administration of KN060 in healthy Chinese subjects. Methods: This single-center, randomized, double-blind, placebo-controlled clinical study was conducted in 38 healthy Chinese subjects. The study included 6 dose groups (0.1, 0.3, 1.0, 2.5, 5.0, and 10.0 mg/kg), with KN060 administered via a single ascending-dose regimen. Results: KN060 demonstrates good tolerability and safety, with no significant treatment-emergent adverse events. A single intravenous infusion of KN060, ranging from 0.1 to 10.0 mg/kg, resulted in an average Conclusion: The study results demonstrated that KN060 was well tolerated and safe. Based on pharmacokinetic and pharmacodynamic data, KN060 is a promising humanized dual-domain antibody simultaneously targeting FXI/FXIa for the prevention of thromboembolic diseases. Trial Registration: https://www.chictr.org.cn, identifier: ChiCTR2200056926; http://www.chinadrugtrials.org.cn, identifier: CTR20222339.

Indexed as

dual-domain antibodyfactor XIpharmacodynamicspharmacokineticssafety

Identifiers

PMID41676355
PMCPMC12887396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.